Protein biomarkers for amyotrophic lateral sclerosis
Document Type
Article
Abstract
Amyotrophic lateral sclerosis (ALS) is a progressive motor neuron disease with largely unknown pathogenesis that typically results in death within a few years from diagnosis. There are currently no effective therapies for ALS. Clinical diagnosis usually takes several months to complete and the long delay between symptom onset and diagnosis limits the possibilities for effective intervention and clinical trials. The establishment of protein biomarkers for ALS may aid an earlier diagnosis, facilitating the search for effective therapeutic interventions and monitoring drug efficacy during clinical trials. Biomarkers could also be used to discriminate between subtypes of ALS, to measure disease progression and to detect susceptibility for developing ALS or monitor adverse effects of drug treatment. The present review will discuss the opportunities and proteomic platforms used for biomarker discovery efforts in ALS, summarizing putative ALS protein biomarkers identified in different biofluids. © 2008 Future Drugs Ltd.
Keywords
Cerebrospinal fluid, Mass spectrometry, Motor neuron disease, Plasma, Proteomics, Serum
Publication Date
4-1-2008
Publication Title
Expert Review of Proteomics
ISSN
14789450
E-ISSN
17448387
Volume
5
Issue
2
First Page
249
Last Page
262
PubMed ID
18466055
Digital Object Identifier (DOI)
10.1586/14789450.5.2.249
Recommended Citation
Ryberg, Henrik and Bowser, Robert, "Protein biomarkers for amyotrophic lateral sclerosis" (2008). Translational Neuroscience. 581.
https://scholar.barrowneuro.org/neurobiology/581